Table 6 Classification of 143 external validation cohort patients into risk groups based on the commercial and RUO ROR scores.

From: Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Commercial Prosigna ROR

RUO ROR (NanoString-derived)

Total

Low

Intermediate

High

Low

2

4

0

6

Intermediate

0

10

17

27

High

0

1

109

110

Total

2

15

126

143

Back to article page